MannKind's Furoscix Auto-Injector Approval, Launch Could Provide Strong Upside to 2026 Revenue Expectation, Wedbush Says

MT Newswires Live

Jul 24

MannKind (MNKD) is expected to get FDA approval for the Furoscix ReadyFlow auto injector by July 26 and launch it in August, providing significant upside to its full-year 2026 revenue expectation, Wedbush Securities said in a research note Friday.

Management reiterated its 2026 ReadyFlow net revenue guidance of $110 million to $120 million, assuming about 14% of annual dispenses are generated in Q1 and without any significant contribution from ReadyFlow, the firm noted. Given that assumption, the auto-injector approval could provide strong revenue upside and diversify commercial portfolio, the note added.

Wedbush expects Furoscix revenue growth to resume in Q2, projecting revenue of $22.5 million versus consensus of $24.7 million. With ReadyFlow's contribution, the brokerage expects revenue growth to further accelerate in the second half.

The company's research suggests approximately 65% of healthcare providers expect to increase the use of Furoscix upon ReadyFlow's approval, the brokerage noted.

Wedbush kept an outperform rating on MannKind with a price target of $8 per share.

Price: 4.05, Change: +0.16, Percent Change: +4.11

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2653033054"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653033054\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653033054?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 22:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653033054","market":"sg","top_or_hot":-1,"title":"MannKind's Furoscix Auto-Injector Approval, Launch Could Provide Strong Upside to 2026 Revenue Expectation, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> MannKind (MNKD) is expected to get FDA approval for the Furoscix ReadyFlow auto injector by July 26 and launch it in August, providing significant upside to its full-year 2026 revenue expectation, Wedbush Securities said in a research note Friday.</p><p>Management reiterated its 2026 ReadyFlow net revenue guidance of $110 million to $120 million, assuming about 14% of annual dispenses are generated in Q1 and without any significant contribution from ReadyFlow, the firm noted. Given that assumption, the auto-injector approval could provide strong revenue upside and diversify commercial portfolio, the note added.</p><p>Wedbush expects Furoscix revenue growth to resume in Q2, projecting revenue of $22.5 million versus consensus of $24.7 million. With ReadyFlow's contribution, the brokerage expects revenue growth to further accelerate in the second half.</p><p>The company's research suggests approximately 65% of healthcare providers expect to increase the use of Furoscix upon ReadyFlow's approval, the brokerage noted.</p><p>Wedbush kept an outperform rating on MannKind with a price target of $8 per share.</p><p>Price: 4.05, Change: +0.16, Percent Change: +4.11</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MannKind's Furoscix Auto-Injector Approval, Launch Could Provide Strong Upside to 2026 Revenue Expectation, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMannKind's Furoscix Auto-Injector Approval, Launch Could Provide Strong Upside to 2026 Revenue Expectation, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-24 22:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> MannKind (MNKD) is expected to get FDA approval for the Furoscix ReadyFlow auto injector by July 26 and launch it in August, providing significant upside to its full-year 2026 revenue expectation, Wedbush Securities said in a research note Friday.</p><p>Management reiterated its 2026 ReadyFlow net revenue guidance of $110 million to $120 million, assuming about 14% of annual dispenses are generated in Q1 and without any significant contribution from ReadyFlow, the firm noted. Given that assumption, the auto-injector approval could provide strong revenue upside and diversify commercial portfolio, the note added.</p><p>Wedbush expects Furoscix revenue growth to resume in Q2, projecting revenue of $22.5 million versus consensus of $24.7 million. With ReadyFlow's contribution, the brokerage expects revenue growth to further accelerate in the second half.</p><p>The company's research suggests approximately 65% of healthcare providers expect to increase the use of Furoscix upon ReadyFlow's approval, the brokerage noted.</p><p>Wedbush kept an outperform rating on MannKind with a price target of $8 per share.</p><p>Price: 4.05, Change: +0.16, Percent Change: +4.11</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凯德生物医疗","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2653033054","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653033054","pubTimestamp":1784905158,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"MannKind  is expected to get FDA approval for the Furoscix ReadyFlow auto injector by July 26 and launch it in August, providing significant upside to its full-year 2026 revenue expectation, Wedbush Securities said in a research note Friday.Management reiterated its 2026 ReadyFlow net revenue guidance of $110 million to $120 million, assuming about 14% of annual dispenses are generated in Q1 and without any significant contribution from ReadyFlow, the firm noted. Given that assumption, the auto-injector approval could provide strong revenue upside and diversify commercial portfolio, the note added.Wedbush expects Furoscix revenue growth to resume in Q2, projecting revenue of $22.5 million versus consensus of $24.7 million. With ReadyFlow's contribution, the brokerage expects revenue growth to further accelerate in the second half.The company's research suggests approximately 65% of healthcare providers expect to increase the use of Furoscix upon ReadyFlow's approval, the brokerage note","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗"},"translate_title":"Wedbush 表示，MannKind's Furoscix 自动注射器的批准和推出可能会为 2026 年的收入预期带来强劲的上涨空间","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1.5},"content_text":"MannKind (MNKD) is expected to get FDA approval for the Furoscix ReadyFlow auto injector by July 26 and launch it in August, providing significant upside to its full-year 2026 revenue expectation, Wedbush Securities said in a research note Friday.Management reiterated its 2026 ReadyFlow net revenue guidance of $110 million to $120 million, assuming about 14% of annual dispenses are generated in Q1 and without any significant contribution from ReadyFlow, the firm noted. Given that assumption, the auto-injector approval could provide strong revenue upside and diversify commercial portfolio, the note added.Wedbush expects Furoscix revenue growth to resume in Q2, projecting revenue of $22.5 million versus consensus of $24.7 million. With ReadyFlow's contribution, the brokerage expects revenue growth to further accelerate in the second half.The company's research suggests approximately 65% of healthcare providers expect to increase the use of Furoscix upon ReadyFlow's approval, the brokerage noted.Wedbush kept an outperform rating on MannKind with a price target of $8 per share.Price: 4.05, Change: +0.16, Percent Change: +4.11","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}